Platelet-to-lymphocyte ratio and overall survival according to first-line immunotherapy exposure in metastatic melanoma: a multicentre retrospective cohort study

Purpose We evaluated whether associations between inflammatory and nutritional biomarkers and overall survival (OS) differed according to first-line immunotherapy (IO) exposure in metastatic melanoma. Methods This multicentre retrospective cohort included 236 patients treated during 2010–2025. Seven biomarkers, platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio, C-reactive protein, albumin, lactate dehydrogenase (LDH), and body mass index, were evaluated using Cox regression. Interaction models were adjusted for Eastern Cooperative Oncology Group performance status and LDH (performance status alone for LDH), with Bonferroni correction for seven tests ( p < 0.0071). Extended sensitivity analyses were exploratory. Results Among 236 patients, 81 (34.3%) received first-line IO, and 142 deaths occurred. Elevated PLR was associated with shorter OS in the IO (HR, 6.03; 95% CI, 2.44–14.95) and non-IO (HR, 1.54; 95% CI 1.05–2.24) groups. The adjusted PLR-by-treatment interaction was significant (HR ratio, 4.41; 95% CI, 1.71–11.36; p = 0.002) and remained significant after adjustment for calendar period and BRAF status. In the 2022–2025 subgroup, the interaction was not statistically significant ( p = 0.055). An exploratory second-line analysis using reassessed PLR ( n = 114) yielded an unadjusted interaction HR ratio of 2.95 (95% CI 1.22–7.13; p = 0.016). SII showed no significant interaction (HR ratio, 2.08; p = 0.108), nor did the remaining biomarkers. Conclusions PLR showed treatment-dependent prognostic heterogeneity, but these observational findings do not establish predictive utility for treatment selection. External validation is required.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-21
DOI
https://doi.org/10.1007/s12672-026-06342-w
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Platelet-to-lymphocyte ratio and overall survival according to first-line immunotherapy exposure in metastatic melanoma: a multicentre retrospective cohort study

Serdar Karakaya, Özgen Ahmet Yıldırım, Erkan Erdur, İbrahim Karadağ et al.
Discover Oncology
Inflammatory Biomarkers in Disease Prognosis
article

Platelet-to-lymphocyte ratio and overall survival according to first-line immunotherapy exposure in metastatic melanoma: a multicentre retrospective cohort study

Serdar Karakaya, Özgen Ahmet Yıldırım, Erkan Erdur, İbrahim Karadağ, Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş
article en

Abstract

Purpose We evaluated whether associations between inflammatory and nutritional biomarkers and overall survival (OS) differed according to first-line immunotherapy (IO) exposure in metastatic melanoma. Methods This multicentre retrospective cohort included 236 patients treated during 2010–2025. Seven biomarkers, platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio, C-reactive protein, albumin, lactate dehydrogenase (LDH), and body mass index, were evaluated using Cox regression. Interaction models were adjusted for Eastern Cooperative Oncology Group performance status and LDH (performance status alone for LDH), with Bonferroni correction for seven tests ( p < 0.0071). Extended sensitivity analyses were exploratory. Results Among 236 patients, 81 (34.3%) received first-line IO, and 142 deaths occurred. Elevated PLR was associated with shorter OS in the IO (HR, 6.03; 95% CI, 2.44–14.95) and non-IO (HR, 1.54; 95% CI 1.05–2.24) groups. The adjusted PLR-by-treatment interaction was significant (HR ratio, 4.41; 95% CI, 1.71–11.36; p = 0.002) and remained significant after adjustment for calendar period and BRAF status. In the 2022–2025 subgroup, the interaction was not statistically significant ( p = 0.055). An exploratory second-line analysis using reassessed PLR ( n = 114) yielded an unadjusted interaction HR ratio of 2.95 (95% CI 1.22–7.13; p = 0.016). SII showed no significant interaction (HR ratio, 2.08; p = 0.108), nor did the remaining biomarkers. Conclusions PLR showed treatment-dependent prognostic heterogeneity, but these observational findings do not establish predictive utility for treatment selection. External validation is required.

Discover Oncology
Ministry of Health (TR), Ankara Atatürk Eğitim ve Araştırma Hastanesi (TR), Memorial Ankara Hospital (TR), Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR)
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon